Fundz

Noema Pharma raised $147 Million in a Series B financing round led by EQT Life Sciences to support its Phase 2 trials for CNS disorders.

PRIVATEDec 11, 2024

Amount Raised

$147 Million

Round Type

Series B

BaselBiotechnologyHealth CareTherapeutics

Investors

ForbionJeito CapitalSofinnova PartnersGilde HealthcarePolaris PartnersInvusUPMC EnterprisesEQT Life Sciences

Description

Noema Pharma successfully closed a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised to approximately $147 million. This financing will support Noema Pharma’s four active Phase 2 trials, with key data readouts anticipated in 2025.

Who to call at Noema Pharma, and when

A new round usually means Noema Pharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Noema Pharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Noema Pharma, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Noema Pharma

Location

Basel, Basel City, Switzerland

About

Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025. Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including EQT Life Sciences, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Noema Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for Noema Pharma's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Noema Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.